|Bid||20.15 x 900|
|Ask||27.58 x 800|
|Day's Range||24.06 - 24.43|
|52 Week Range||19.10 - 39.87|
|Beta (3Y Monthly)||2.15|
|PE Ratio (TTM)||N/A|
|Earnings Date||Dec 15, 2016 - Dec 19, 2016|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||59.20|
We at Insider Monkey have gone over 700 13F filings that hedge funds and prominent investors are required to file by the SEC. The 13F filings show the funds’ and investors’ portfolio positions as of September 30th. In this article we look at what those investors think of Albireo Pharma, Inc. (NASDAQ:ALBO). Albireo Pharma, Inc. […]
Albireo Pharma, Inc. (ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced the European Commission has granted orphan designation to lead product candidate A4250, an ileal bile acid transporter (IBAT) inhibitor, for the treatment of biliary atresia, a rare and life-threatening liver disease with no approved pharmacologic treatment option. A4250 also holds orphan drug designations in both the U.S. and EU for the treatment of progressive familial intrahepatic cholestasis (PFIC), Alagille syndrome and primary biliary cholangitis (PBC).
Odevixibat selected as International Nonproprietary Name (INN) for A4250 A4250 granted Fast Track and additional Orphan Drug designations A4250 Phase 3 trial progressing as.
BOSTON, Nov. 08, 2018 -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced.
BOSTON, Nov. 06, 2018 -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced.
“Market volatility has picked up again over the past few weeks. Headlines highlight risks regarding interest rates, the Fed, China, house prices, auto sales, trade wars, and more. Uncertainty abounds. But doesn’t it always? I have no view on whether the recent volatility will continue for a while, or whether the market will be back […]
NEW YORK, Oct. 26, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
NEW YORK, NY / ACCESSWIRE / August 7, 2018 / Albireo Pharma, Inc. (NASDAQ: ALBO ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 7, 2018 at 8:30:00 AM Eastern ...